Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients


Monoclonal antibody Trastuzumab/Herceptin is considered as frontline therapy for Her2-positive breast cancer patients. However, it is not effective against several patients due to acquired or de novo resistance. In last one decade, several assays have been performed to understand the mechanism of Herceptin resistance with/without supplementary drugs. This… (More)
DOI: 10.1038/srep04483


3 Figures and Tables


Citations per Year

Citation Velocity: 25

Averaging 25 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.